The Relationship Between Reaction Time and Executive Functions in Female Athletes
NCT05789472, Not applicable, Completed, Medipol University
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | The Relationship Between Reaction Time and Executive Functions in Female Athletes | ClinicalTrials.gov |
| NCT number | NCT05789472 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 66 participants, actual | ClinicalTrials.gov |
| Lead sponsor | Medipol University | ClinicalTrials.gov |
| Conditions | Assessment | ClinicalTrials.gov |
| Interventions | Assessment | ClinicalTrials.gov |
| First posted | 2023-03-29 | ClinicalTrials.gov |
| Last updated | 2024-11-06 | ClinicalTrials.gov |
Registered outcomes 4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | BlazePod Reaction Time Determination Test | 1 day | The BlazePod test, which includes "pods" equipped with touch sensors and LED lights, will be used to evaluate the reaction time. In the evaluation, the number of 15 seconds of touch (number), the reaction time (ms) for the visual response of 15 seconds of touch, and the average reaction time will be analyzed. | ClinicalTrials.gov |
| Primary | Forward-Backward Number Range Test | 1 day | The test consists of two parts as forward and backward range. In the forward number range, the numbers are read at one-second intervals and the patient is asked to repeat the numbers read randomly in the same order. In the back number range, it is requested to repeat the numbers read from the end to the beginning. As you succeed, it continues by increasing one step. If the patient fails twice in a row for both sections, the test is discontinued. Generally, the difference between the forward and backward number range is expected to be two digits. The highest score that can be obtained for the forward range is 8 points, and 7 for the backward range, for a total of 15 points. | ClinicalTrials.gov |
| Primary | Stroop Test | 1 day | The test consisting of 6 lines of random blue, green, red colors and including three basic tasks; In the first task, the individual is asked to name the colors in the box. In case of successful completion, the second task, the words written with the same colors, is asked to be read and the time is kept. In the third task, the words are asked to inhibit reading and to say in which color they are written. The time to finish the test, the number of errors, and the number of spontaneous corrections are noted. | ClinicalTrials.gov |
| Primary | Tracking Test | 1 day | The trail riding test consists of two parts, A and B. In part A, the participants are asked to combine the circles with the numbers in the correct order and following each other (1-2-3-4-5...). In section B, there are letters and numbers placed in circles. Participants are asked to combine letters and numbers in the correct sequence (1-A-2-B-3-C-4-D...). The times of both sections are recorded. The trailing test requires visuospatial processing and motor skills. Particularly, part B is widely used in the measurement of complex attention, planning, set-changing, and reaction inhibition among executive functions. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 1
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Primary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)